Trial Profile
Pramipexole in Bipolar Disorder: Targeting Cognition (PRAM-BD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 May 2021
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary)
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- Acronyms PRAM-BD
- 06 May 2021 Primary endpoint (MATRICS Consensus Cognitive Battery) has not been met as per results published in the Journal of Clinical Psychopharmacology
- 06 May 2021 Results published in the Journal of Clinical Psychopharmacology
- 14 Jan 2019 Status changed from recruiting to completed.